|
Active tuberculosis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
We concluded that differential miR-29a expression in active TB was not causative for impaired IFN-γ expression.
|
24981709 |
2014 |
|
Acute Chest Syndrome
|
0.010 |
Biomarker
|
disease |
BEFREE |
Two miRNAs (hsa-miR-29 and hsa-miR-1) and three TFs (NFIC, NFKB1 and RELA) were critical genes involved in pathological process of ACS.
|
31550669 |
2019 |
|
Acute GVH disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
Serum miR-29a is also elevated as early as 2 wk before time of diagnosis of aGVHD compared with time-matched control subjects.
|
28159900 |
2017 |
|
Acute monocytic leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
The tumour-suppressive miR-29a/b1 cluster is regulated by CEBPA and blocked in human AML.
|
20628397 |
2010 |
|
Acute myocardial infarction
|
0.010 |
Biomarker
|
disease |
BEFREE |
Receiver operating characteristic curve analysis showed that miR-29a-3p could be used to screen AMI patients from healthy controls.
|
31410131 |
2019 |
|
Acute pancreatitis
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
To investigate the expression of miR-29a in rat acute pancreatitis and its functional role in AR42J cell apoptosis.
|
27239114 |
2016 |
|
Adenocarcinoma
|
0.010 |
Biomarker
|
group |
BEFREE |
Two microRNA panels yielded high diagnostic accuracy in discriminating SCLC from NSCLC (miR-29a and miR-375; area under the curve [AUC], 0.991 and 0.982 for training and validation data set, respectively) and in differentiating SQ from AC (miR-205 and miR-34a; AUC, 0.977 and 0.982 for training and validation data set, respectively) in FFPE surgical lung specimens.
|
23043084 |
2012 |
|
Adenocarcinoma of lung (disorder)
|
0.010 |
Biomarker
|
disease |
BEFREE |
miR‑29a suppresses IL‑13‑induced cell invasion by inhibiting YY1 in the AKT pathway in lung adenocarcinoma A549 cells.
|
29620222 |
2018 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
Expression of two miRNA, miR-200C and miR-29a, was down-regulated in EGCs compared to normal mucosa or adenomas.
|
30258124 |
2018 |
|
Adenoma
|
0.020 |
AlteredExpression
|
group |
BEFREE |
In contrast, although exosomal miR-21 and miR-29a levels in adenoma patients were significantly higher than those of healthy volunteers, only exosomal miR-21 significantly correlated with adenoma size and total adenoma number, and could discriminate patients with high-risk adenomas.
|
27760147 |
2016 |
|
Adenomatous Polyps
|
0.010 |
Biomarker
|
disease |
BEFREE |
Compared to exosomal miRNAs, serum levels of miR-21, miR-29a and miR-92a are superior diagnostic biomarkers in patients with high-risk adenomatous polyps.
|
27760147 |
2016 |
|
Adult Acute Myeloblastic Leukemia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Acute myeloid leukemia (AML) is a heterogeneous disease with different clinical course and prognosis. microRNA-29 (miR-29) family of non-coding small RNAs can play an important role in pathogenesis of AML, but also can influence response to therapy.The purpose of the study was to evaluate miR-29c expression in AML patients in relationship to clinical parameters and response to chemotherapy, including azacitidine.
|
26862847 |
2016 |
|
Adult Burkitt Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mature sequences of miR-29a/b/c were transfected to the BL cell lines BL41 and Raji, and evaluated for DNMT3B, MCL1, BIM, CDK6, AKT and TCL1 protein expression as well as for MCL-1 and CDK6 mRNA expression.
|
29318382 |
2018 |
|
Adult Burkitt Lymphoma
|
0.020 |
Biomarker
|
disease |
BEFREE |
BL tumour samples and BL cell lines presented miR‑29a/b1 and miR‑29b2/c genes methylated in CpG sites located in both the promoter and enhancer regions.
|
31173259 |
2019 |
|
Adult Ependymoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The most specific were miR-10a and miR-29a low expression in LGG non-responders, miR-135a and miR-146b over-expression in ependymoma non-responders, and miR-135b overexpression in medulloblastoma non-responders.
|
29658967 |
2019 |
|
Adult Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
MicroRNA-29a inhibits glioblastoma stem cells and tumor growth by regulating the PDGF pathway.
|
31482267 |
2019 |
|
Adult Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
miR-29s (including miR-29a-c) have been confirmed to be effective tumor suppressors for a variety of malignant tumors including glioblastoma.
|
25625222 |
2015 |
|
Adult Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
MiR-29a-Mediated CD133 Expression Contributes to Cisplatin Resistance in CD133<sup>+</sup> Glioblastoma Stem Cells.
|
30267383 |
2018 |
|
Adult Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
We have characterized a novel miR-29a/QKI-6/WTAP axis in GSCs, which may provide theoretical support for the treatment of glioblastoma with miR-29a agomirs.
|
28212562 |
2017 |
|
Adult Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
CCK-8, wound healing, and transwell invasion assays were carried out to analyze the effects of miR-29a in glioblastoma cells. qRT-PCR, luciferase reporter, and western blot experiments were done to validate the targeting of TRAF4/Akt pathway by miR-29a.
|
30186853 |
2018 |
|
Adult Glioblastoma
|
0.060 |
Biomarker
|
disease |
BEFREE |
We observed that miR-29a is among the microRNAs that are most positively-correlated with PTEN copy number in glioblastoma, and that miR-29a promotes glioblastoma growth and invasion in part by targeting PTEN.
|
30683134 |
2019 |
|
Adult Hepatocellular Carcinoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
microRNA-29 can regulate expression of the long non-coding RNA gene MEG3 in hepatocellular cancer.
|
21625215 |
2011 |
|
Adult Liver Carcinoma
|
0.010 |
Biomarker
|
disease |
BEFREE |
Among the altered miRNA, miR-29a seemed to take a role in the mechanism of arsenic trioxide in liver cancer therapy.
|
21175813 |
2011 |
|
Adult Medulloblastoma
|
0.010 |
AlteredExpression
|
disease |
BEFREE |
The most specific were miR-10a and miR-29a low expression in LGG non-responders, miR-135a and miR-146b over-expression in ependymoma non-responders, and miR-135b overexpression in medulloblastoma non-responders.
|
29658967 |
2019 |
|
Adult-Onset Still Disease
|
0.010 |
Biomarker
|
disease |
BEFREE |
We discovered a panel including 3 miRNAs (miR-142-5p, miR-101-3p, and miR-29a-3p) that can predict the probability of AOSD with an area under the receiver operating characteristic (ROC) curve of 0.8250 in training and validation sets.
|
30687316 |
2018 |